CYAD(Delisted)
Celyad OncologyยทNASDAQ
--
--(--)
Is CYAD undervalued or overvalued?
- CYAD scores 0.00/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, 0.00% net margin, 0.00 P/E ratio, 0.00 P/B ratio, and 0.00% earnings growth, these metrics solidify its Neutral investment rating.
